| Drug Name | Angiotec (Enalapril) |
|---|---|
| Drug Class |
Anti-hypertension
|
| Risk minimization type | |
| Specialty (Theraputic area) |
Endocrine
Cardiology
|
| Risk |
restriction of combined use of medicines affecting the renin-angiotensin aldosterone system(RAAS) |
| Dear Healthcare provider letter DHPC |
|